Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Has Consensus Price Target of $42.75 According to Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $42.75.

Separately, Weiss Ratings downgraded shares of Kailera Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, October 6th.

Kailera Therapeutics Stock Up 9.0%

Kailera Therapeutics stock opened at $11.71 on Friday. The firm has a fifty day simple moving average of $14.48. Kailera Therapeutics has a 52 week low of $9.76 and a 52 week high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.35). Research analysts predict that Kailera Therapeutics will post -3.89 EPS for the current year.

Institutional Investors Weigh In On Kailera Therapeutics

Several hedge funds have recently modified their holdings of the stock. Atlas Venture Life Science Advisors LLC purchased a new stake in Kailera Therapeutics in the second quarter valued at approximately $113,923,000. Wellington Management Group LLP acquired a new position in Kailera Therapeutics during the second quarter worth approximately $64,308,000. Frazier Life Sciences Management L.P. purchased a new position in Kailera Therapeutics during the second quarter worth approximately $24,233,000. State Street Corp purchased a new position in Kailera Therapeutics during the second quarter worth approximately $19,126,000. Finally, Squarepoint Ops LLC purchased a new position in Kailera Therapeutics during the second quarter worth approximately $993,000.

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for obesity and other chronic metabolic diseases. The company’s research is centered on therapies designed to address weight management and related health conditions.

Kailera’s pipeline includes ecnoglutide, an investigational, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist being evaluated for potential use in obesity and metabolic disorders. The company continues to advance clinical development and assess additional opportunities in the metabolic disease sector.

Kailera Therapeutics is focused primarily on research and development activities, with its programs intended for potential commercialization in international markets subject to clinical, regulatory and other approvals.